The Texas maternal mortality and morbidity review committee, formed in 2013, has come under scrutiny due to the recent appointment of an anti-abortion activist physician, Ingrid Skop, MD, to a position that was originally intended for a rural community member. This decision has raised questions about the composition of the committee and whether it truly represents the diverse voices needed to address maternal health issues effectively. Furthermore, the process of selecting committee members appears to have been contentious, with the state health department’s deputy commissioner ultimately choosing Dr. Skop over another applicant after facing division among committee members. This raises concerns about transparency and the potential for bias in the selection process.
Inadequate Response to Medical Device Recalls
A report from CBS News and KFF Health News has shed light on the concerning lack of oversight when it comes to medical device recalls. Despite the FDA issuing recalls for devices with serious flaws that can cause harm or death, the response often falls short of removing the devices from circulation. Instead, companies may opt to provide corrective actions such as retraining doctors or repairing the devices, leaving patients at risk of continued harm. This raises questions about the prioritization of patient safety and the effectiveness of the current recall system. The case of Abbott’s MitraClip line, which experienced multiple recalls but remained in use, highlights the potential dangers of allowing flawed devices to remain on the market.
UnitedHealth’s Questionable Practices with QuantaFlo Device
UnitedHealth’s use of the QuantaFlo device for screening peripheral artery disease (PAD) has raised concerns about the accuracy of the diagnosis and the potential for overdiagnosis. The device, which was approved through an accelerated FDA pathway, was widely utilized by UnitedHealth in its primary care clinics and home visit program, leading to a significant increase in reimbursement from Medicare Advantage. However, doctors and experts have raised doubts about the reliability of the device, citing false positives that may have resulted in unnecessary treatment for patients. The discrepancy between UnitedHealth’s internal guidelines for screening and its insurance plan medical reviewers’ advice highlights the conflicting interests at play when it comes to healthcare decisions.
Overall, these investigative reports point to systemic issues within the healthcare industry that have significant implications for patient safety and quality of care. From questionable appointments to key committees to inadequate responses to medical device recalls and the prioritization of profit over patient well-being, there are clear areas in need of improvement and reform. It is essential for stakeholders in the healthcare system to critically examine these reports and take action to address the underlying issues that threaten the integrity of the industry and the well-being of patients.
Leave a Reply